The Trump administration has proposed a Medicare rule that it says could save patients about $1.1 billion in the first year by changing how hospitals are reimbursed for drugs bought through the 340B discount program. According to AP, the proposal would set payments closer to the discounted acquisition cost rather than allowing higher reimbursement formulas to flow through to patient charges.
The policy revives a long-running dispute over who should capture the savings from discounted outpatient drugs. The administration frames the rule as a direct affordability measure for Medicare Part B patients. Hospital groups argue that 340B margins help support uncompensated care, rural services, and programs for low-income communities, so cutting reimbursements could shift costs elsewhere or reduce services.
The legal history also matters. A prior version of a similar payment cut was blocked after litigation, and this proposal appears designed to answer that vulnerability with survey data and revised formulas. That does not eliminate the likelihood of another court fight, but it clarifies the administration's theory: Medicare patients should not pay coinsurance based on prices far above what covered hospitals actually pay.
The practical question is distributional. Patients using affected drugs could see lower out-of-pocket costs, while hospitals that rely heavily on 340B spreads could face budget pressure. The next signal will be the formal rulemaking record, especially whether the agency quantifies hospital-side effects as carefully as patient savings.